Symplicity Spyral Renal Denervation System
Medtronic, Inc. · Decision date Sep 10, 2026
What did the FDA approve?
The FDA record P220026/S014 covers a labeling supplement for the Symplicity Spyral Renal Denervation System, an ablation catheter for renal denervation under product code QYI, submitted by Medtronic, Inc. The supplement type is the Normal 180 Day Track No User Fee, and its listed reason is a labeling change tied to post-approval study data.
The stated purpose is inclusion of data from post-approval studies in labeling. That statement describes a labeling action, not an independent finding of safety or clinical effectiveness. As a supplement to P220026, it modifies labeling within the existing PMA rather than approving the system anew. The record does not identify which studies, which labeling sections, or the content of any changed text.
FDA approval order statement
inclusion of data from post-approval studies in labeling
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 10, 2026
- FDA change category
- Labeling Change - PAS
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P220026/S014
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- Decision code
- APPR
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Ablation catheter, renal denervation.
- Applicant
- Medtronic, Inc.
- Product code
- QYI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220026. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220026 · Original PMA
Symplicity Spyral Renal Denervation System
P220026/S014 received
Application receipt date recorded by FDA.
P220026/S014 · FDA decision
Normal 180 Day Track No User Fee
P220026/S019 · Related supplement
Symplicity G3 Renal Denervation RF Generator
Timeline entries are records held by MedtechLedger for P220026. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220026
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Nov 17, 2023 | FDA | |
Symplicity G3 Renal Denervation RF GeneratorP220026/S019 | Medtronic, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220026/S014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
